GLPwatch
Papers (10401)
Page 57 of 174, ranked by citation count.
- Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
- Liraglutide Lowers Body Weight Set Point in DIO Rats and its Relationship with Hypothalamic Microglia Activation.
- Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.
- Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
- The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study.
- Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.
- Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway.
- Increased myocardial vulnerability to ischemia-reperfusion injury in the presence of left ventricular hypertrophy.
- Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.
- Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
- Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1.
- Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.
- Liraglutide improved inflammation <i>via</i> mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin.
- Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
- Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy.
- Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes.
- Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
- Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
- Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
- Egg Microneedle for Transdermal Delivery of Active Liraglutide.
- Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.
- Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2).
- Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study.
- Liraglutide reduces body weight by upregulation of adenylate cyclase 3.
- LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet.
- The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
- Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.
- Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development.
- Ozempic face: A new challenge for facial plastic surgeons.
- Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.
- Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
- Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents.
- The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes.
- A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.
- Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
- Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.
- Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility.
- Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
- Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
- Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.
- Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.
- Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
- Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
- Construction and Evaluation of Liraglutide Delivery System based on Milk Exosomes: A New Idea for Oral Peptide Delivery.
- Semaglutide in Cystic Fibrosis-Related Diabetes.
- Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
- Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.
- A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
- LncRNA-Malat1 is Involved in Lipotoxicity-Induced ß-cell Dysfunction and the Therapeutic Effect of Exendin-4 via Ptbp1.
- Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.
- Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.
- Long-term functional alterations following prenatal GLP-1R activation.
- Liraglutide for psychiatric disorders: clinical evidence and challenges.
- Effect of Lipidation on the Structure, Oligomerization, and Aggregation of Glucagon-like Peptide 1.
- Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
- Semaglutide is effective in achieving weight loss in liver transplant recipients.
- GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
- Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemia.
- Attempted suicide with liraglutide overdose did not induce hypoglycemia.